Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

CLS signs agreement with IGT for development and commercialization of product for MR generated temperature monitoring

Clinical Laserthermia Systems AB (publ) and Image Guided Therapy SA (IGT)  have signed an agreement, in line with the ”term sheet” previously communicated. The purpose of the agreement is to develop and commercialize a software product offering doctors MR-generated, optimal conditions for viewing, measuring and controlling tissue temperatures during treatment with laser ablation and CLS’ immune stimulating imILT® procedure. The objective is to make the product compatible with MR systems from all leading vendors. With this new product offering

Pihlajalinna Plc publishes Interim Report for January 1–September 30, 2018 on Thursday, November 1, 2018

Pihlajalinna Plc                  Press Release                     17 October 2018 at 10.00 Pihlajalinna Plc publishes Interim Report for January 1–September 30, 2018 on Thursday, November 1, 2018 Interim Report Pihlajalinna Plc will publish the Interim Report for the period January 1–September 30, 2018 on Thursday, November 1, 2018 at 8.00 a.m. The release will be available on the company website investors.pihlajalinna.fi. Press and analyst meeting A meeting for analysts and the press, conducted in Finnish, will be held on Thursday, November 1, 2018 at 10.00 a.m. The

A functional home – more than the sum of its square metres

YIT CORPORATION News, October 17, 2018 at 10:00 a.m.Convenient housing is an issue that goes beyond mere square metres. It is also a question of our individual needs and preferences. Living design philosophy finds out what makes a home functional and everyday life easier. As the old joke goes, every Finn’s dream home is a mansion by a lake in the middle of Helsinki. But when we wake up and smell the coffee, most of us would be happy with a home in a good location that is big enough for our needs and makes our everyday life easier. YIT conducted the Tribe survey for the first time in

Invitation to UPM's webcast and press conference on third quarter 2018 results

(UPM, Helsinki, 17 October 2018 at 10:00 EET) - UPM will publish its third quarter 2018 Interim Report on 24 October 2018 at 09:30-10:00 EET. The report will be available on the company's website at www.upm.com  after publishing. UPM's President and CEO Jussi Pesonen will present the financial results in a webcast and a conference call for analysts and investors, held in English language, on 24 October 2018 at 13:15 EET. Later in the afternoon, Jussi Pesonen will present the results in a press conference held in Finnish language at the UPM Group

Archeological surveys completed

The Company has received notice from the Directorate for Cultural Heritage, confirming that the archeological surveys pursuant to the approved zoning plan at Engebø now have been fully completed and that the area has been clarified for construction activities. CEO Ivar S. Fossum comments “we are pleased to receive this confirmation which represents elimination of a potential risk and another step in the right direction towards realization of the Engebø rutile and garnet project.” For questions please contact CEO Ivar S. Fossum, telephone +47 930 96 850.Oslo, 17 October 2018Nordic

Senzime reports from the American Society of Anesthesiologists (ASA) Annual Meeting in San Francisco, USA

News: Uppsala, 17 October 2018.For more than 68 years, the ASA Annual Meeting has been the most comprehensive anesthesia-related educational event in the world, bringing together top influential and notable professionals in anesthesiology, pain medicine and critical care medicine. Numerous presenters discussed patient safety initiatives and necessary steps to reduce adverse events in the perioperative period. Hundreds of technical, scientific and educational exhibits displaying and demonstrating the latest products, services and industry research. During the exhibition Senzime had the

Medivir scales back research costs to focus on clinical development

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announced today plans to reduce activities not critical to its development pipeline of drug candidates as part of its enhanced focus on clinical stage projects. As part of this plan, Medivir will notify the Public Employment Office of potential employee redundancies impacting approximately 60 positions, mainly within pre-clinical research and administration. Medivir will also call for consultations with the trade unions regarding the possible consequences for the employees. The plan is to reduce Medivir’s annual running cost base,

Nordic Nanovector – Financial Calendar

Oslo, Norway, 17 October 2018 FINANCIAL YEAR 2018 Quarterly Report - Q3   06.11.2018 (changed from 21.11.2018) Quarterly Report - Q4   27.02.2019 FINANCIAL YEAR 2019 Annual General meeting 25.04.2019 Quarterly Report - Q1   23.05.2019 Half-yearly Report        22.08.2019 Quarterly Report - Q3   21.11.2019 The dates are subject to change. The time and location of the presentations will be announced in due time. This information is published pursuant to the requirements set out in the Continuing obligations. For further information, please contact: IR

Interim Management Statement January-September 2018

Highlights during the third quarter · Adjusted net asset value, based on estimated market values for the major subsidiaries and partner-owned investments within Patricia Industries, amounted to SEK 420,572 m. (SEK 550 per share) on September 30, 2018. Adjusted net asset value increased by SEK 26,402 m., or 7 percent during the quarter. · Reported net asset value amounted to SEK 372,371 m. (SEK 487 per share) on September 30, 2018, an increase of SEK 24,514 m., or 7 percent, during the quarter. · Listed Core Investments generated a total return* of 9 percent. · Based on

Nordic Nanovector ASA: Change of Date for Q3 2018 Results Presentation and Webcast

Oslo, Norway, 17 October 2018 Nordic Nanovector ASA (OSE: NANO) announces it will present its results for the third quarter 2018 on Tuesday, 6 November 2018 (previously scheduled for Tuesday, 21 November), and will host a results presentation and webcast on the same day (details will be announced nearer the time). During this presentation, the Company will present updated clinical results from the LYMRIT 37-01 trial with Betalutin® in relapsed/refractory indolent non-Hodgkin’s lymphoma patients. These results will be published on 1 November in an abstract* that will be presented in a

Invitation to presentation of Handicare´s Interim report January – September 2018

On the 24th of October at 08.00, Handicare will publish its Interim report January – September 2018.At 10.00 AM (CET) the same day, the company holds a conference call, where President and CEO Staffan Ternström presents the report together with CFO Stephan Révay. After the presentation follows a Q&A session. The conference call will be held in English. The Interim report and a presentation will be available at www.handicaregroup.com/investors 

We spend up to 90% of our time indoors – Tikkurila contributing to cleaner indoor air development

People spend about 90% of their time indoors, at home, at school, at work and in public places.* This is why indoor air quality is extremely important for people’s health. Tikkurila has joined the Indoor Air Quality Ecosystem (IAQe) initiative. The purpose of the IAQe initiative, launched in 2018 and funded by Business Finland, is to develop new solutions that improve indoor air quality, bring together Finnish expertise and export them to the international markets. The objective is to work together to improve indoor air quality and to find new solutions in the form of joint and

MAG Interactive AB (publ) presents interim report Sep 2017 – Aug 2018

COMMENT FROM DANIEL HASSELBERG, CEO Revenue growth thanks to new games “Revenues in the reporting period June-August increased compared to the previous quarter thanks to our two new games Paint Hit and Word Domination. During the reporting period we saw an average of 15 million active players on a monthly basis, which is up significantly compared to the previous quarter and more than double the amount compared to the same period previous year. The contribution from games increased 20% compared to previous year. During the reporting period, we were able to significantly increase our

ACCOUNTING INVESTIGATION CONFIRMS PRELIMINARY FINDINGS REGARDING REIMBURSEMENTS TO FORMER CEO

The preliminary findings of an independent investigation into expenses reimbursed to co-founder and former CEO Henrik Ljungcrantz were disclosed via press release on July 24, 2018. The final report from PwC has now confirmed these preliminary findings.The board of directors, in line with what was stated in the July 24 press release, has submitted the investigation report to the Swedish Economic Crime Authority for further processing, and will seek to recover the reimbursed expenses identified by the investigation as incorrectly paid out plus costs for the investigation itself. For more

Mycronic receives order for advanced maskwriter

Mycronic has received an order for a Prexision-800 from a customer in Asia. The system is configured with limited functionality and is scheduled for delivery in the second quarter of 2019. The order, which was booked in the fourth quarter, is valued at between USD 30-35 million and also includes certain upgrades to the customer’s existing system. Mycronic’s Business Area Pattern Generators provides mask writers for manufacturing photomasks in several fields of application. These mainly consist of display manufacturing (TV, smartphones and tablets) and applications in the multi-purpose

Hansa Medical Receives FDA Fast Track Designation for Imlifidase for Transplantation

Lund, Sweden, October 17, 2018- Hansa Medical AB (NASDAQ Stockholm: HMED), the leading biopharma company focusing on inhibition of immunoglobulin G (IgG)-mediated immunopathologies, today announced that the U.S. Food and Drug Administration (FDA) has granted imlifidase Fast Track Designation for the investigation of imlifidase for transplantation.Imlifidase (IdeS) is an enzyme in late-stage clinical development that specifically cleaves IgG antibodies, thereby inhibiting the IgG-mediated immune response. Hansa Medical is initially developing imlifidase as a proprietary treatment to enable

Castellum’s Interim Report January-September 2018: A record strong quarter – 13% growth in income from property management

· Income for the period January-September 2018 amounted to MSEK 4,141 (MSEK 3,866 corresponding period previous year). · Income from property management amounted to MSEK 2,219 (1,956), corresponding to SEK 8.12 (7.16) per share, an increase of 13%. · Changes in value on properties amounted to MSEK 3,150 (2,069) and on derivatives to MSEK 202 (204). · Net income after tax for the period amounted to MSEK 5,051 (3,424), corresponding to SEK 18.49 (12.53) per share. · EPRA NAV amounted to SEK 168 (142) per share, an increase of 18%. · Net investments amounted to MSEK 3,009 (4,560)

Detection Technology Plc's financial calendar for 2019

Detection Technology Plc Company Announcement 17 October 2018 at 09:00 (EEST) Detection Technology Plc's financial calendar for 2019 Detection Technology Plc will disclose the following financial releases in 2019: · Financial statements review 2018: 1 February 2019 · Business review January-March 2019: 26 April 2019 · Half-yearly report January-June 2019: 2 August 2019 · Business review January-September 2019: 25 October 2019 The financial statements and annual review for 2018 will be published latest on 7 March 2019 on the company's website. The Annual General

myFC develops technology that secures the company’s recurring revenues from fuel, and protects users and manufacturers from counterfeit fuel cards

myFC has developed the system and technologies to secure that myFC’s unique certified fuel chemistry can correctly identify a myFC PowerCard, the company’s original, patented fuel card. Only PowerCards will be accepted at start of energy generation for a smartphone or other device.myFC today announces it has a patent pending that protects the fuel chemistry of its PowerCard. Specifically, the patent covers the technology allowing the device to immediately recognize if a power card is in fact a myFC original PowerCard, safe for the intended use, and ensuring the device does not accept any

BASWARE INTERIM REPORT JANUARY 1 – SEPTEMBER 30, 2018 (IFRS)

Cloud order intake growth accelerates to 29 percentJuly-September 2018: · Net sales EUR 33 991 thousand (EUR 35 827 thousand): decrease of 5.1 percent, organic growth at constant currencies 5.2 percent · Organic cloud revenue growth at constant currencies 15.0 percent, amounting to 66.0 percent (56.0 %) of net sales · Adjusted EBITDA EUR -877 thousand (EUR 3 661 thousand) · Adjusted operating profit/loss EUR -3 600 thousand (EUR 1 361 thousand) · Adjusted earnings per share (diluted) EUR -0.21 (0.06) · Operating profit/loss EUR -3 787 thousand (EUR 1 205 thousand) ·

Basware announces EUR 1 billion revenue growth vision

Basware’s vision is to deliver the best global solution for networked purchasing, invoicing and paying. All organisations need to manage their purchasing processes from procurement through to handling invoices and paying them. Currently many organisations only have unsophisticated or partial tools to manage these processes and as a result many are faced with unmanaged spending, inefficient manual and paper-based processes and poor visibility of cashflows. Basware offers a uniquely complete solution for these challenges that is differentiated by the Basware Network, the largest e-

Redeye: Acconeer should be on your radar

We initiate coverage of Acconeer, a fabless semiconductor company that develops and sells radar sensors. The characteristics of the product and the business model imply scalability and a good case for high margins. Thus, we argue that Acconeer should be on investors' radars. Download the initial research report: http://bit.ly/2yGBaN3 Start following companies at Redeye to recieve the latest research withtin Life Science and Technology. This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/

There are no items matching the current filter
There are no more items matching the current filter
Back to top